Rafael Leite Pacheco

Rafael Leite Pacheco

Auto-generated profile, based on publicly available information

Rafael Leite Pacheco

Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil; Centro Universitário São Camilo (CUSC), São Paulo - SP, Brazil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco
RPRafael Leite Pacheco
Rafael Leite Pacheco
ÂBÂngela Maria Bagattini
Ângela Maria Bagattini
RRRachel Riera
Rachel Riera
Aims to identify, systematically evaluate and summarise the best available evidence on the frequency of long COVID (post‐acute COVID‐19 syndrome), its clinical manifestations and the criteria used for diagnosis. Methods Systematic review conducted with a comprehensive search including formal databases, COVID‐19 or SARS‐CoV‐2 data sources, grey literature, and manual search. We considered for inclusion clinical trials, observational longitudinal comparative and non‐comparative studies, cross‐sectional, before‐and‐after and case series. We assessed the methodological quality by using specific tools based on the study designs. We presented the results as a narrative synthesis regarding frequency and duration of long COVID, signs and symptoms, criteria used for diagnosis, and potential risk factors. Results We included 25 observational studies with moderate to high methodological quality, considering 5,440 participants. The frequency of long COVID ranged from 4.7 to 80%, and the most prevalent signs/symptoms were chest pain (up to 89%), fatigue (up to 65%), dyspnea (up to 61%), and cough and sputum production (up to 59%). Temporal criteria used to define long COVID varied from 3 to 24 weeks after acute phase or hospital discharge. Potentially associated risk factors were old age, female sex, severe clinical status, a high number of comorbidities, hospital admission, and oxygen supplementation at the acute phase. However, limitations related to study designs added uncertainty to this finding. None of the studies assessed the duration of signs/symptoms. Conclusion The frequency of long COVID reached up to 80% over the studies included and occurred between 3 to 24 weeks after acute phase or hospital discharge. Chest pain, fatigue, dyspnea and cough were the most reported clinical manifestations attributed to the condition. Based on this systematic review findings, there is an urgent need to understand this emerging, complex and challenging medical condition. Proposals for diagnostic criteria and standard terminology are welcome.

12 December 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
AMAna Luiza C Martimbianco
Ana Luiza C Martimbianco
GPGustavo Jm Porfírio
Gustavo Jm Porfírio
RPRafael L Pacheco
Rafael L Pacheco
MTMaria Regina Torloni
Maria Regina Torloni
RRRachel Riera
Rachel Riera

1 March 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco
KSKamilla Mayr Martins Sá
Kamilla Mayr Martins Sá
GSGiovanna Marcílio Santos
Giovanna Marcílio Santos
ESElaine Marcílio Santos
Elaine Marcílio Santos
RPRafael Leite Pacheco
Rafael Leite Pacheco
RRRachel Riera
Rachel Riera
The aim of this study was to identify the frequency of Cochrane systematic reviews and Cochrane systematic reviews protocols using (or planning to use) the risk of bias 2.0 tool to assess the risk of bias of the included randomized clinical trials. This is a meta-research study. We included Cochrane systematic reviews or Cochrane systematic reviews protocols that planned to include randomized clinical trials. We assessed the Cochrane Database of Systematic Reviews and screened for issues published after the launch of risk of bias 2.0 tool (2019-2022). Two independent investigators performed the study selection and data extraction. We analyzed 440 Cochrane systematic reviews and 536 Cochrane systematic reviews protocols. Overall, 4.8% of the Cochrane systematic reviews and 28.5% of the Cochrane systematic reviews protocols used or planned to use risk of bias 2.0 tool. Although low, adherence is increasing over time. In 2019, 0% of Cochrane systematic reviews used risk of bias 2.0 tool, compared to 24.1% in 2022. In Cochrane systematic reviews protocols, adherence increased from 6.9% in 2019 to 41.5% in 2022. A total of 274 (62.1%) Cochrane systematic reviews had their protocols published before 2018; only one used risk of bias 2.0 tool and reported the change of versions in the "Differences between protocol and revision" section. The Cochrane's risk of bias 2.0 tool has low adherence among Cochrane protocols and systematic reviews. Further efforts are necessary to facilitate the implementation of this new tool.

1 December 2020 in Journal of Evidence-Based Dental Practice
Verified
Journal Article
Closed access
GSGiovanna Marcílio Santos
Giovanna Marcílio Santos
RPRafael Leite Pacheco
Rafael Leite Pacheco
SBSandra KALIL BUSSADORI
Sandra KALIL BUSSADORI
ESElaine Marcílio Santos
Elaine Marcílio Santos
RRRachel Riera
Rachel Riera
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco

3 February 2022 in The Breast
Verified
Journal Article
Open access
GMGustavo Marta
Gustavo Marta
RRRachel Riera
Rachel Riera
RPRafael Leite Pacheco
Rafael Leite Pacheco
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco
IMIcro Meattini
Icro Meattini
PPPhilip M.P. Poortmans
Philip M.P. Poortmans
We provide a critical assessment regarding current evidence for the use of moderately hypofractionated irradiation for patients with breast cancer. The aim of the study was to summarize the available evidence regarding outcomes after moderately hypofractionated compared with conventional radiation doses in the post-operative treatment of patients with breast cancer. The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS databases were searched until March 25, 2021. All randomized phase 3 clinical trials that compared moderately hypofractionated with conventional radiation doses in the post-operative treatment of patients with breast cancer were selected. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. Eight clinical trials satisfied the eligibility criteria and were the focus of the analysis. A total of 12,139 breast cancer patients was randomly assigned for moderately hypofractionated compared with conventional irradiation. Meta-analysis of the trials regarding local recurrence, loco-regional recurrence, disease-free survival, and overall survival outcomes did not demonstrate any significant difference between moderately hypofractionated irradiation and conventional radiation doses groups. The rate of severe side effects was low in both groups; acute and late side effects and cosmesis were similar or even tended to be lower after moderately hypofractionated than after conventional irradiation. Moderately hypofractionated is at least as effective and safe as conventional radiation irradiation regimens and should be considered as a treatment option for most, if not all, breast cancer patients.

16 December 2019 in Trials
Verified
Journal Article
Open access
PDF file
VMVânia Mozetic
Vânia Mozetic
LLLetícia Leonel
Letícia Leonel
RPRafael Leite Pacheco
Rafael Leite Pacheco
CLCarolina de Oliveira Cruz Latorraca
Carolina de Oliveira Cruz Latorraca
TGTaís Guimarães
Taís Guimarães
RRRachel Riera
Rachel Riera
Background: A considerable amount of randomized controlled trials (RCTs) have been published on statins and/or fibrates for diabetic retinopathy, a clinical condition associated with high social and economic burden. Adherence to the CONSORT statement items is imperative to ensure transparency and reproducibility in clinical research. The aim of this study is to assess the reporting quality and the adherence to CONSORT of RCTs assessing statins and/or fibrates for diabetic retinopathy. Methods: We conducted a critical appraisal study at Discipline of Evidence-based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (Unifesp). A sensitive literature search was performed to identify all relevant RCTs, with no time or language limits. Two authors independently evaluated the reporting quality of the selected RCTs using the CONSORT statement as a standard. Results: Thirteen reports of RCTs were included in this study. The adherence of the reports to CONSORT items ranged from 24% to 68%. The median score was 11 (interquartile range (IQR) 8 to 13). When analyzed separately, the methods sections of the reports had a median of three items (IQR 2 to 4) judged adherent to the methods items of CONSORT (items 3 to 12). The most underreported items were those related to trial design, title and abstract, allocation concealment, implementation of the randomization sequence, and blinding. Other important items, such as the one related to the description of the inclusion criteria, also had low adherence. Conclusions: The overall adherence to the CONSORT checklist items was poor, especially in the items related to the methods section. RCT reports on statins and/or fibrates for diabetic retinopathy must be optimized to avoid reporting biases and to improve transparency and reproducibility.